Pharmacogenetic issues in thorough QT trials

被引:7
作者
Judson, Richard S.
Salisbury, Benjamin A.
Reed, Carol R.
Ackerman, Michael J.
机构
[1] SpyroPharma, Guilford, CT USA
[2] Clin Data Inc, New Haven, CT USA
[3] Mayo Clin, Coll Med, Sudden Death Genom Lab, Rochester, MN USA
关键词
D O I
10.1007/BF03256454
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Drug-induced QT prolongation (DI-LQT), through its associated arrhythmias, is a leading cause of drugs being withdrawn from the market. As a consequence, the US FDA and other regulatory agencies are mandating that all new drugs go through a so-called 'Thorough QT' (TQT) study to evaluate the potential for 'QT liability', specifically the potential for a drug to cause a discernible increase in the QT interval. Several genetic factors that modulate the risk of DI-LQT have been discovered. These are genes responsible for the congenital long QT syndrome, drug metabolism genes (mainly CYP2D6 and CYP3A4), and genes in other regulatory pathways. Here, we briefly review the links between genetic variants and drug-induced QT risk, and propose approaches to consider for using pharmacogenetics in planning and analyzing TQT studies.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 76 条
[21]   The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations [J].
Ficker, E ;
Obejero-Paz, CA ;
Zhao, S ;
Brown, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (07) :4989-4998
[22]  
Fujita Ken-ichi, 2004, Drug Metabolism and Drug Interactions, V20, P195
[23]  
GEORGE AL, 2002, Patent No. 6458542
[24]  
Hara M, 1998, J PHARMACOL EXP THER, V285, P1068
[25]   The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology [J].
Haverkamp, W ;
Breithardt, G ;
Camm, AJ ;
Janse, MJ ;
Rosen, MR ;
Antzelevitch, C ;
Escande, D ;
Franz, M ;
Malik, M ;
Moss, A ;
Shah, R .
CARDIOVASCULAR RESEARCH, 2000, 47 (02) :219-233
[26]   Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management [J].
Hohnloser, SH .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 :G82-G89
[27]   Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter:: A prospective study [J].
Houltz, B ;
Darpö, B ;
Edvardsson, N ;
Blomström, P ;
Brachmann, J ;
Crijns, HJGM ;
Jensen, SM ;
Svernhage, E ;
Vallin, H ;
Swedberg, K .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1998, 21 (05) :1044-1057
[28]  
*ICH HARM TRIP GUI, E14 ICH HARM TRIP GU
[29]   DHPLC analysis of potassium ion channel genes in congenital long QT syndrome [J].
Jongbloed, R ;
Marcelis, C ;
Velter, C ;
Doevendans, P ;
Geraedts, J ;
Smeets, H .
HUMAN MUTATION, 2002, 20 (05) :382-391
[30]  
Judson R, 2005, CARDIAC SAFETY OF NONCARDIAC DRUGS, P83, DOI 10.1007/978-1-59259-884-7_5